Advertisement


Othman Al-Sawaf, MD, PhD, on Previously Untreated CLL: Fixed-Duration vs Continuous Targeted Treatment

ASH 2025

Advertisement

Othman Al-Sawaf, MD, PhD, of the University Hospital of Cologne, presents results from the phase III CLL17 trial, which compared continuous ibrutinib monotherapy to fixed-duration venetoclax plus obinutuzumab to fixed-duration venetoclax plus ibrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL) (Abstract 1). 



Related Videos

Multiple Myeloma

Dory Abelman, PhD(c), HBHSc, on Newly Diagnosed Multiple Myeloma: Ultradeep Whole-Genome Sequencing of cfDNA

Dory Abelman, PhD(c), HBHSc, of the University of Toronto, discusses findings that support the feasibility of ultradeep cell-free DNA whole-genome sequencing for comprehensive genomic profiling in patients with multiple myeloma, which may be a less invasive alternative to bone marrow biopsy (Abstract 495). 

Leukemia

Ibrahim Aldoss, MD, on Older Adults With B-Cell ALL: CD19 CAR T-Cell Therapy

Ibrahim Aldoss, MD, of City of Hope, presents findings from a small, single-center study of patients aged 55 years and older with B-cell acute lymphoblastic leukemia (ALL) in first complete remission who were treated with CD19-directed CAR T-cell therapy. Researchers found the therapy was safe, resulted in low-grade adverse events, and led to preliminary durable measurable residual disease response (Abstract 443). 

Leukemia

Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy

Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)and could challenge the current treatment standard (Abstract 6). 

Leukemia

Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy

Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicinbased therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) (Abstract 441). 

Multiple Myeloma

Jack Khouri, MD, on Multiple Myeloma: Burixafor and Propranolol With G-CSF Before Transplant

Jack Khouri, MD, of Cleveland Clinic, describes the findings of a phase II trial which investigated the safety and efficacy of burixafor (GPC-100), a potent and selective small -molecule antagonist of CXCR4, and propranolol with granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPC) in patients with multiple myeloma. Researchers aimed to boost the bone marrow HPC niche and optimize mobilization in patients with multiple myeloma eligible for autologous hematopoietic cell transplant (Abstract 1050). 

Advertisement

Advertisement




Advertisement